Clinical trials: Hepatitis A
Hepatitis C
Way to Cure HCV Adherence
This is a 3-arm, multi-center, patient-randomized, field evaluation of the "Way to Cure" behavioral interventions on medication adherence in HCV.
- Trial name
- WTC (NCT02472925)
- Testing
- MedSignals Pill Box
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Pennsylvania
Diphtheria, Polio
Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants
This is a follow-up of Study A3L10 (NCT00315055) Immunogenicity To describe the antibody persistence following a primary series vaccination of either DTaP-IPV-HB-PRP~T or PENTAXIM™ and ENGERIX B®.
- Conditions
- Diphtheria, Polio, Pertussis, Hepatitis B
- Trial name
- NCT00619502
- Testing
- DTaP-IPV-HB-PRP~T vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Chronic Hepatitis b
A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo
This study is a post-marketing surveillance of Besivo in participants with chronic hepatitis B.
- Trial name
- NCT03642340
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Viral Hepatitis C
Serious Game Interventions to Reduce Viral Hepatitis C Among PLWH-MSM
The study is aimed to provide high-risk, HIV-infection, men who have sex with men (MSM) with healthcare education regarding viral hepatitis C, through either serious game intervention or traditional online health education.
- Trial name
- NCT05751889
- Testing
- Serious Game, Traditional Health Education
- Where
- Taiwan
- Volunteers
- 1,320 people
- Sponsor
- National Taiwan University Hospital
Chronic Hepatitis B
A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B
This is a randomized, double-blinded, placebo-controlled, phase IIa study to evaluate safety and efficacy of TQ-A3334 combined with entecavir in the untreated or HBV DNA negative subjects with Chronic Hepatitis B.
- Trial name
- NCT04180150
- Testing
- TQ-A3334, Entecavir Tablet
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatitis C, Chronic
Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C
The purpose of this study is to examine the rapid virologic response (RVR) at combination therapy (CT) Week 4 between groups receiving a standard combination peginterferon alfa-2b/viramidine dosing regimen versus a cohort that…
- Trial name
- NCT00305383
- Testing
- Viramidine, Peginterferon alfa-2b
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Hepatitis B
A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection
This study is A multicenter, randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the efficacy and safety of HT-101 injection combined with HT-102 injection in patients with chronic hepatitis B.
- Trial name
- NCT07245953
- Testing
- HT-101, HT-102
- Where
- 12 sites in China
- Volunteers
- 60 people
- Sponsor
- Suzhou HepaThera Biotech Co., Ltd.
Chronic Hepatitis B
Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)
The study is to evaluate the efficacy and safety of AHB-137 in CHB participants. The total duration of the study, including screening phase, treatment phase and follow-up phase.
- Trial name
- NCT06829329
- Testing
- AHB-137, NAs
- Where
- 6 sites in China
- Volunteers
- 105 people
- Sponsor
- Ausper Biopharma Co., Ltd.
Hepatitis C, Chronic
A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy
The purpose of this study is to evaluate the efficacy and safety of TMC435 in combination with peginterferon alfa-2a (PegIFNα-2a) and ribavirin in genotype 1 hepatitis C virus (HCV)-infected participants who relapsed after…
- Trial name
- NCT01290731
- Testing
- TMC435, Pegylated interferon (pegIFN alpha-2a), Ribavirin (RBV)
- Where
- 10 sites in Japan
- Volunteers
- 49 people
- Sponsor
- Janssen Pharmaceutical K.K.
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)
The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- LIFE-C (NCT02615145)
- Volunteers
- 472 people
- Sponsor
- AbbVie
Chronic Hepatitis b
Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.
Treatment of CHB patients with genotypic resistance to NUCs has been problematic due to the lack of data from randomized trials.
- Trial name
- NCT03241641
- Testing
- Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Young-Suk Lim
Chronic Hepatitis B
A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients
This is a open, randomized, parallel study. Subjects will have Clevudine or Entecavir therapy for 48 weeks(Clevudine:Entecavir = 2:1), and subjects who have Complete Response(HBV DNA negative and ALT normal) will have follow-up…
- Trial name
- NCT01266005
- Testing
- Clevudine, Entecavir
- Where
- South Korea
- Volunteers
- 75 people
- Sponsor
- Bukwang Pharmaceutical
Hepatitis C
The DETECT HCV Screening Trial
The investigators propose to compare the effectiveness of nontargeted rapid opt-out hepatitis C (HCV) screening versus targeted rapid opt-out HCV screening using recommended risk characteristics in multiple urban emergency…
- Trial name
- DETECT HCV (NCT04003454)
- Testing
- HCV Screening
- Where
- 3 sites in United States
- Volunteers
- 147,533 people
- Sponsor
- Denver Health and Hospital Authority
Healthy
Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine
The purpose of the study is to evaluate the safety and immunogenicity of an investigational hepatitis B vaccine (HEPLISAV) in adults 18 to 70 years of age.
- Trial name
- NCT02117934
- Testing
- HEPLISAV, Engerix-B
- Where
- 40 sites in United States
- Volunteers
- 8,374 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Hepatitis B
Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib
Persistence of seroprotective antibody concentrations \& immunological memory shown by the ability to mount a response to a challenge dose of HBV vaccine
- Trial name
- NCT00356564
- Testing
- hepatitis B vaccine
- Where
- 42 sites in Germany
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Poliomyelitis, Tetanus
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).
This study will evaluate the immunogenicity of the co-administration of different combinations of DTPa, IPV, hepatitis B, Hib and Men C vaccines during the first year of life.
- Conditions
- Poliomyelitis, Tetanus, Acellular Pertussis, Hepatitis B
- Trial name
- NCT00352963
- Testing
- Study vaccines: IH+Hib-MenC/NVC; Control: IH+Meningitec
- Where
- 22 sites in Spain
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic
Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
The purpose of this study is to evaluate if a 12-week total regimen of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) (T12/PR12) is safe and effective in subjects who have the…
- Trial name
- CONCISE (NCT01459913)
- Testing
- Telaprevir, Pegylated Interferon Alfa-2a, Ribavirin
- Where
- 83 sites in United States, Austria and 4 more
- Volunteers
- 239 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatocellular Carcinoma in Hepatitis C Virus Infected Patients
Application of the Stem Cell Therapy in the End Stage Liver Disease and Assessment Its Consequences in the Quality of Live Style as Well as Development of HCC.
Prospective study to calculated the incidence of hepatocellular carcinoma in hepatitis C virus infected patients after stem cell therapy.
- Trial name
- NCT01729221
- Where
- Egypt
- Volunteers
- 280 people
- Sponsor
- Cairo University
Liver Disease Chronic, Hepatitis B Virus
Efficacy of HBVaxpro40© and Fendrix© in Patients With Chronic Liver Disease.
Background: Cirrhotic patients have an increased risk of infections. In these patients is important to prevent hepatitis B virus (HBV) infection, as it may cause a deterioration of liver function.
- Trial name
- NCT03459521
- Testing
- Fendrix or HBVAXPRO 40
- Where
- Spain
- Volunteers
- 125 people
- Sponsor
- Corporacion Parc Tauli
Chronic Hepatitis b
Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients
The aim of the prospective study is to determine whether combination/ sequential therapy with Entecavir, Peginterferon alfa-2b and immunomodulators Granulocyte Macrophage Colony Stimulating Factor (GMCSF)+vaccine could induce…
- Trial name
- NPGV (NCT03332329)
- Testing
- Entecavir, Granulocyte Macrophage Colony Stimulating Factor, Y peginterferon alfa-2b
- Volunteers
- 15 people
- Sponsor
- Qin Ning